Document:

<PAGE>

                                                                  EXHIBIT 10.314

                                 AMENDMENT NO. 2

                                       TO

               AGREEMENT BETWEEN GEN-PROBE INCORPORATED AND CHIRON
                                   CORPORATION

         This Amendment is made effective as of February 1, 2000, to the
Agreement between Gen-Probe Incorporated and Chiron Corporation dated as of June
11, 1998, as previously amended (the "Agreement").

         The parties hereby agree to amend the Agreement as follows:

         1. DEFINITIONS. Capitalized terms not defined in this Amendment
shall have the meanings set forth in the Agreement.

         2. APPLICABLE TO CHIRON AND GEN-PROBE ONLY. [PROVISION ASSIGNED].
Chiron retained all rights and obligations under the Agreement with respect
to the Blood Screening Field. This Amendment is effective as between Chiron
and Gen-Probe, [PROVISION ASSIGNED].

         3. CONFIDENTIALITY AND INVENTION OWNERSHIP.

            A. Section 1.23 of the Agreement is hereby amended by placing a
period (".") after the word "Agreement" at the end of clause (ii) in the first
paragraph, and deleting the following words:

            "and (iii) marked, identified as, or otherwise acknowledged to
            be confidential at the time of disclosure to the other party."

            B. Section 8.1 of the Agreement is hereby amended by deleting the
following sentence at the end of the Section:

            "Notwithstanding the foregoing and Section 1.23, unless otherwise
            mutually agreed in writing, neither party shall have any obligation
            to the other party pursuant to this Article 8 or pursuant to Article
            9 with respect to use of Confidential Information of the Disclosing
            Party unless, prior to disclosure, such Confidential Information is
            specifically identified in writing to the Receiving Party and the
            Receiving Party agrees in writing to accept such Confidential
            Information."

                                  Page 1 of 2
<PAGE>

            C. Section 9.1.4(b) of the Agreement is hereby amended to read in
full as follows:

            "(b) was made through or with, and would not have been made but for,
            the Inventing Party's use of Confidential Information of the other
            party (the "Disclosing Party"), if such information was confidential
            when the invention was made."

         By the signatures of their authorized officers below, Gen-Probe and
Chiron adopt this amendment as of February 1, 2000.

CHIRON CORPORATION                         GEN-PROBE INCORPORATED

By       /s/ RAJEN K. DALAL                By       /s/ HENRY L. NORDHOFF
         ------------------                         ----------------------
                                                    Henry L. Nordhoff
         Title: President,                          President and
         Blood Testing                              Chief Executive Officer
         Chiron

                                  Page 2 of 2<PAGE>

                                                            EXHIBIT 10.509

                        DESCRIPTION OF CHIRON CORPORATION'S
               2000 EXECUTIVE OFFICERS VARIABLE COMPENSATION PROGRAM

Decisions on compensation (base salary and variable compensation) of Chiron
Corporation's ("Chiron" or the "Company") executive officers are made by the
Compensation Committee of the Board of Directors.

For 2000, the Compensation Committee continued the Company's approach that
base salaries for executive officers should be measured by reference to the
median (50th percentile) of salaries for benchmark positions in comparator
companies. Further, the Compensation Committee provided that a significant
portion of total cash compensation (salary plus variable compensation) in the
form of annual variable cash compensation potential should be "at risk,"
dependent upon individual, business unit and overall Company performance.
Variable cash compensation for executive officers overall was targeted to
yield total cash compensation at the 50% percentile, but with the opportunity
to significantly exceed the 50% percentile of total cash compensation as
shown by comparative data, in the case of outstanding Company, business unit,
and individual performance.

The Compensation Committee based its decisions regarding variable
compensation for executive officers upon its evaluation of performance
against pre-established performance metrics developed at the Company,
business unit and functional or corporate unit level.

Variable compensation for the Chairman and Chief Executive Officer is based
on the performance of the Company as measured against the pre-established
Company metrics composed of financial objectives and business innovation
milestones.

Executive officers responsible for business units or major functional or
corporate units are eligible for variable compensation based on the
pre-established Company metrics and on the achievement of their respective
business, functional, or corporate unit metrics.<PAGE>

[CHIRON LETTERHEAD]

                                                       SEAN P. LANCE
                                            Chairman and Chief Executive Officer

20 February, 2001

Dr. Lewis T. "Rusty" Williams
125 Chapel Drive
Mill Valley, CA  94941

Dear Rusty,

         I am writing to confirm certain changes in the terms of your employment
with Chiron. We received the Board's approval for these terms at the Board
Meeting of 16 February 2001.

1. DEFINITION OF ROLE AND TRANSITION. You have indicated your desire to seek a
new professional challenge and to step down from service as head of R&D at
Chiron. We will launch immediately a search for a successor. Between now and the
end of February, I will work with you to define a new role for you within Chiron
or in association with Chiron. This new role would become effective after a
period of transition, but generally we would expect it to be in place in the
May-June timeframe. The new role would not include continued services on the
Board of Directors. Accordingly, unless we agree to the contrary with the
Nominating Committee's approval, you would not stand for re-election at the May
Annual General Meeting.

2. IMMEDIATE OBJECTIVES. Between now and May 31, as part of your
responsibilities as head of R&D, you will continue to be responsible, subject to
our normal approval processes, for refinement and implementation of R&D
strategy, including:

-    Initiatives to achieve excellence in development of novel products,
     including any necessary revision to our organization, processes, systems
     and perhaps staffing;
-    Refining and "right-sizing" of our research efforts, including
     identification of the resource requirements for the next 3-5 years and the
     platforms, approaches and organizations and transitional staffing necessary
     to achieve our strategic plan and maintain a highly productive and
     sustainable research program; and

<PAGE>

Dr. Williams
20 February, 2001

-    Organizing and recruiting a Scientific Advisory Board with world-class
     participants and processes to add value to Chiron.

         Beyond May 31, your role will change. I encourage you to remain as an
employee of Chiron after May 31, 2001. We contemplate that you would pass to a
successor your responsibilities as head of R&D and we would need to agree on
your new role. It might focus on early stage research initiatives such as
functional genomics and proteomics and specific leadership of our efforts to
advance our most promising preclinical projects into clinical development
rapidly and with robust development plans. This new role as an employee might be
less than full-time; in which case we contemplate appropriate adjustment in your
compensation.

         However, I also recognize that you ultimately may choose to leave
Chiron to pursue new professional challenges. In which case, I support the
development of a mutually agreeable consulting arrangement in the areas of
S*Bio, proteomics, and/or other areas of possible mutual interest. If you leave
Chiron for a position in academia, we will enter into a consulting agreement for
one year to engage approximately 20-40% of your time with compensation to be the
vesting of 20,000 additional shares of your restricted stock. This consulting
arrangement might provide for the transfer from Chiron to your new academic
setting of mutually agreed upon projects and related personnel (not exceeding
4-5 scientists at the principal scientist level or below) all on terms to be
agreed. Further, we would expect, under such consulting agreement, that you
would continue your active scientific involvement in those projects in the
Biological Discovery and Genomic Groups in which you have participated directly
as senior scientific mentor, including participation in scientific publications,
as appropriate. The consulting arrangement, of course, could be renewed on
mutually agreeable terms. If you should subsequently join a biotech or
pharmaceutical company, the consulting arrangement would terminate and a
pro-rated settlement of the restricted stock vesting would then be made, unless
your new employer was a collaborator with Chiron under terms acceptable to
Chiron dealing with conflicts of interest, competition and solicitation of
employees.

<PAGE>

3. RESTRICTED STOCK. In consideration of your services with Chiron until May 31,
2001 we will recommend to the Board that 40,000 shares of your January 2, 1998
restricted stock grant be made available to you for accelerated vesting if and
when you choose to leave Chiron for a new position in an academic setting or in
a commercial setting that does not compete with Chiron for corporate
opportunities or employees. We have agreed that any position with S*Bio or a
Singapore-based venture fund or a proteomic start-up that supports Chiron's
proteomic strategy would be deemed not to compete with Chiron for this purpose.
Further, your service beyond May 31, 2001 as an employee or in a consulting
capacity, other than the consulting arrangement in academia discussed above,
will result in a further acceleration of vesting of this restricted stock grant
at the rate of 1667 shares per month on a full-time basis, or a pro-rated amount
on a part-time basis, subject to appropriate non-compete and non-solicitation
covenants. If you leave employment status, your stock options will cease to vest
and must be exercised within 90 days, in accordance with their current terms.

4. CONSTRUCTIVE TERMINATION. In view of your request and agreement that we
restructure your work within Chiron and that you transition out of the position
of President of R&D, you agree that future changes in your position and/or
responsibilities within Chiron, or as a consultant if you choose to leave, shall
not trigger a lump sum severance payment or acceleration of vesting of your
restricted stock as contemplated in our letter agreement of January 27, 1998.

         If these changes are consistent with your understanding, please sign
and return to Linda Short a copy of this letter.

Yours sincereley,

/s/ SEAN

Sean P. Lance

<PAGE>

Dr. Williams
20 February, 2001

Agreed:

/s/ Lewis T. Williams
----------------------------------------
Lewis T. "Rusty" Williams, M.D., Ph.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00020-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00020-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00020-of-00352.parquet"}]]